CIK 0000818686
- Large accelerated filer
TEVA PHARMACEUTICAL INDUSTRIES LTD
Sign in to watch- Ticker
- TEVA
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Israel
- Entity type
- Operating
- Phone
- +972 39148213
- Business address
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED, 124 DVORA HANEVI'A ST., TEL AVIV, Israel
- Former names
- TEVA PHARMACEUTICAL INDUSTRIES LIMITED
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $33,242,786
- in 10 filings, $10.6M under 10b5-1 plans
Net −$33,242,786. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-02-09 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise | +16,120 | 38,873.51 | ||
| 2020-02-09 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise · Restricted Share Units | −16,120 | 32,241 | ||
| 2020-02-09 | Drape Eric Executive VP Global Operations | Option exercise | +6,567 | 23,762 | ||
| 2020-02-09 | Drape Eric Executive VP Global Operations | Option exercise · Restricted Share Units | −6,567 | 13,135 | ||
| 2020-02-09 | Dethlefs Sven EVP Global Marketing&Portfolio | Option exercise | +13,135 | 23,729.7 | ||
| 2020-02-09 | Dethlefs Sven EVP Global Marketing&Portfolio | Option exercise · Restricted Share Units | −13,135 | 26,270 | ||
| 2020-02-09 | Daniell Richard Exec. VP, European Commercial | Option exercise | +13,135 | 14,811 | ||
| 2020-02-09 | Daniell Richard Exec. VP, European Commercial | Option exercise · Restricted Share Units | −13,135 | 26,270 | ||
| 2019-12-31 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise | +4,640 | 25,212.51 | ||
| 2019-12-31 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −2,459 | $9.92 | $24K | 22,753.51 |
| 2019-12-31 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise · Restricted Share Units | −4,640 | 0 | ||
| 2019-12-02 | Fridriksdottir Hafrun Executive VP, Global R&D | Sale | −4,310 | $10.49 | $45K | 20,572.51 |
| 2019-11-30 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise | +8,133 | 24,882.51 | ||
| 2019-11-30 | Fridriksdottir Hafrun Executive VP, Global R&D | Option exercise · Restricted Share Units | −8,133 | 0 | ||
| 2019-11-05 | McClellan Michael James EVP, Chief Financial Officer | Option exercise | +695 | 16,140.27 | ||
| 2019-11-05 | McClellan Michael James EVP, Chief Financial Officer | Sale | −242 | $8.83 | $2K | 15,898.27 |
| 2019-11-05 | McClellan Michael James EVP, Chief Financial Officer | Option exercise · Restricted Share Units | −695 | 0 | ||
| 2019-11-03 | Schultz Kare President and CEO | Option exercise | +63,613 | 63,613 | ||
| 2019-11-03 | Schultz Kare President and CEO | Option exercise · Restricted Share Units | −63,613 | 476,389 | ||
| 2019-09-18 | O'Grady Brendan P. EVP, North America Commercial | Option exercise | +1,241 | 2,629.49 |
Page 61 of 76 · 1,517 trades